%0 Letter
%T A QALY is [still] a QALY is [still] a QALY? : Evaluating proportional shortfall as the answer to the problem of equity in healthcare allocations.
%A Mahdiani H
%A Münch N
%A Paul NW
%J BMC Med Ethics
%V 25
%N 1
%D 2024 Mar 23
%M 38521941
%F 2.834
%R 10.1186/s12910-024-01036-w
%X Despite clinical evidence of drug superiority, therapeutic modalities, like combination immunotherapy, are mostly considered cost-ineffective due to their high costs per life year(s) gained. This paper, taking an ethical stand, reevaluates the standard cost-effectiveness analysis with that of the more recent justice-enhanced methods and concludes by pointing out the shortcomings of the current methodologies.